CAS NO: | 31645-39-3 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | Palifosfamide is a novel DNA alkylator and the active metabolite of ifosfamide, with antitumor activity. | ||||||||||||||||
体外研究 (In Vitro) | Palifosfamide lysine (ZIO-201) is a stable form of palifosfamide. Palifosfamide lysine has broad activity in sarcoma linesin vitro. TheIC50ranges from 2.25 ro 6.75 μM for most cell lines except OS222 (IC50=31.5 μM)[1]. | ||||||||||||||||
体内研究 (In Vivo) | Tumor growth inhibition is seen in both OS31 and OS33 xenografts and the RMS xenograft resulting in a significant difference in event-free survival between the control and the treated groups. Differential gene expression of ALDH3A1 but not ALDH1A1 is noted in the OS31 xenograft[1]. Stabilized palifosfamide administered to mice suppresses MX-1 tumor growth by greater than 80% with 17% complete antitumor responses. Oral bioavailability in rats is 48-73% of parenteral administration, and antitumor activity in mice is equivalent by both routes. Treatment with palifosfamide-tris combined with docetaxelor doxorubicin at optimal regimens results in complete tumor regression in 62-75% of mice[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 221.02 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C4H11Cl2N2O2P | ||||||||||||||||
CAS 号 | 31645-39-3 | ||||||||||||||||
中文名称 | 帕利伐米 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | -20°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 40 mg/mL(180.98 mM;Need ultrasonic) H2O : 14.29 mg/mL(64.65 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|